222 related articles for article (PubMed ID: 36493511)
1. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m
Lin X; Ye R; Li Z; Zhang B; Huang Y; Du J; Wang B; Meng H; Xian H; Yang X; Zhang X; Zhong Y; Huang Z
Drug Resist Updat; 2023 Jan; 66():100908. PubMed ID: 36493511
[TBL] [Abstract][Full Text] [Related]
2. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
[TBL] [Abstract][Full Text] [Related]
3. CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma.
He J; Lan X; Liu X; Deng C; Luo H; Wang Y; Kang P; Sun Z; Zhao L; Zhou X
BMC Cancer; 2023 Mar; 23(1):266. PubMed ID: 36959566
[TBL] [Abstract][Full Text] [Related]
4. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
5. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A.
Zhao W; Xie Y
Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400
[TBL] [Abstract][Full Text] [Related]
6. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
7. Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p / ZFX axis: an in vitro and in vivo study.
Wang L; Li M; Lian R
Histol Histopathol; 2022 Jul; 37(7):637-654. PubMed ID: 35133000
[TBL] [Abstract][Full Text] [Related]
8. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis.
Wang T; Liu Z; She Y; Deng J; Zhong Y; Zhao M; Li S; Xie D; Sun X; Hu X; Chen C
Cancer Lett; 2021 Nov; 520():321-331. PubMed ID: 34389432
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma.
Zhou S; Deng M; Bian X; Shi J; Liang R; Tao M
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):120-127. PubMed ID: 38430032
[TBL] [Abstract][Full Text] [Related]
10. RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway.
Zhang D; Jiang Q; Ge X; Shi Y; Ye T; Mi Y; Xie T; Li Q; Ye Q
Int J Biol Sci; 2021; 17(10):2622-2632. PubMed ID: 34326698
[TBL] [Abstract][Full Text] [Related]
11. m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression.
Zhang H; Wang SQ; Wang L; Lin H; Zhu JB; Chen R; Li LF; Cheng YD; Duan CJ; Zhang CF
Cell Death Dis; 2022 Jul; 13(7):657. PubMed ID: 35902569
[TBL] [Abstract][Full Text] [Related]
12. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
Zhu HE; Yin JY; Chen DX; He S; Chen H
Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
[TBL] [Abstract][Full Text] [Related]
13. Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR/MAPK signaling pathway.
Li M; Wu R; Zhu D; Wang L; Liu S; Wang R; Deng C; Zhang S; Chen M; Lu R; Zhu H; Mo M; Luo Z
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37165929
[TBL] [Abstract][Full Text] [Related]
14. LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1.
Huang J; Pan B; Xia G; Zhu J; Li C; Feng J
Cell Death Dis; 2020 Jul; 11(7):525. PubMed ID: 32655137
[TBL] [Abstract][Full Text] [Related]
15. TRB3 interacts with ERK and JNK and contributes to the proliferation, apoptosis, and migration of lung adenocarcinoma cells.
Cao X; Fang X; Malik WS; He Y; Li X; Xie M; Sun W; Xu Y; Liu X
J Cell Physiol; 2020 Jan; 235(1):538-547. PubMed ID: 31256425
[TBL] [Abstract][Full Text] [Related]
16. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.
Song H; Liu D; Wang L; Liu K; Chen C; Wang L; Ren Y; Ju B; Zhong F; Jiang X; Wang G; Chen ZS; Zou C
Mol Cancer; 2022 Feb; 21(1):43. PubMed ID: 35144642
[TBL] [Abstract][Full Text] [Related]
17. SLC39A5 promotes lung adenocarcinoma cell proliferation by activating PI3K/AKT signaling.
Liu Z; Hu Z; Cai X; Liu S
Pathol Res Pract; 2021 Aug; 224():153541. PubMed ID: 34252710
[TBL] [Abstract][Full Text] [Related]
18. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract][Full Text] [Related]
19. PRKCZ-AS1 promotes the tumorigenesis of lung adenocarcinoma via sponging miR-766-5p to modulate MAPK1.
Wang M; Liao Q; Zou P
Cancer Biol Ther; 2020 Apr; 21(4):364-371. PubMed ID: 31939714
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA miR-3646 promotes malignancy of lung adenocarcinoma cells by suppressing sorbin and SH3 domain-containing protein 1 via the c-Jun NH2-terminal kinase signaling pathway.
Wang C; Cheng B
Bioengineered; 2022 Mar; 13(3):4869-4884. PubMed ID: 35196185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
